Stout Ranks as Top Fairness Opinion Provider in 2023
As a leading transaction opinion provider, Stout leverages its extensive transaction advisory expertise, including valuation, investment banking, financial and tax due diligence, and accounting and reporting advisory services to assist corporate boards and other fiduciaries in making sound business decisions and completing their critical and often highly complex transactions. Since 2012, Stout has consistently ranked as a top fairness opinion provider by LSEG.*
"The transaction market in 2023 was definitely impacted by higher interest rates, resulting in a number of deals being derailed or postponed," said
"Our talented and experienced Transaction Opinions professionals look forward to working with corporate boards, special committees, fund managers, trustees, and other fiduciaries as they navigate the deal market in 2024 and beyond," said
*Based on the total number of deals reported by more than 20 companies since 2012 in LSEG's Global M&A Financial Advisory Review (formerly known as Refinitiv's Mergers and Acquisitions Review). Individual yearly
About Stout
Stout is a global advisory firm specializing in corporate finance, accounting and transaction advisory, valuation, financial disputes, claims, and investigations. We serve a range of clients, from public corporations to privately held companies in numerous industries. Our clients and their advisors rely on our premier expertise, deep industry knowledge, and unparalleled responsiveness on complex matters.
Stout is a trade name for Stout Risius Ross, LLC, Stout Advisors SA, Stout Bluepeak Asia Ltd, Stout GmbH, MB e Associati S.r.l., Stout Park Ltd, and Stout Capital, LLC, a FINRA-registered broker-dealer and SIPC member firm. The terms "Stout" or the "firm" refer to one or more of these legally separate and independent advisory practices.
View original content to download multimedia:https://www.prnewswire.com/news-releases/stout-ranks-as-top-fairness-opinion-provider-in-2023-302039611.html
SOURCE Stout
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
- Quoin Pharmaceuticals reports interim Phase 2/3 data for QRX003
- AiRWA receives Nasdaq deficiency notice over late 10-K filing
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share